Recap: Amicus Therapeutics Q3 Earnings

Amicus Therapeutics FOLD reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM.

Here's what investors need to know about the announcement.

Amicus Therapeutics beat estimated earnings by 36.84%, reporting an EPS of $-0.12 versus an estimate of $-0.19.

Revenue was up $2.15 million from the same period last year.

Last quarter the company beat on EPS by $0.01 which was followed by a 11.33% increase in the share price the next day.

Here's a look at Amicus Therapeutics's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	-0.22	-0.25	-0.16	-0.18
EPS Actual	-0.21	-0.30	-0.29	-0.19
Revenue Estimate	85.89M	77.13M	83.28M	80.11M
Revenue Actual	80.73M	78.72M	82.15M	79.55M

To track all earnings releases for Amicus Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar